The absence of any licensed hantavirus vaccine, combined with extended clinical development timelines, underpins the market's strong 94.5% implied probability against availability in 2026. As of mid-2026, candidates remain in preclinical or early-phase testing following advances like structural mapping and mRNA approaches, with no Phase 3 efficacy trials underway to meet regulatory standards for approval. A May 2026 Andes virus outbreak on a cruise ship highlighted the disease's severity and spurred research interest, yet historical patterns show vaccine licensing requires years beyond initial lab progress. Traders' consensus aligns with official surveillance data showing low case volumes and no accelerated emergency pathways sufficient for this calendar year, though unexpected regulatory fast-tracking or breakthrough trial results could still alter trajectories before year-end.
Experimentelle KI-generierte Zusammenfassung mit Polymarket-Daten. Dies ist keine Handelsberatung und spielt keine Rolle bei der Auflösung dieses Marktes. · AktualisiertHantavirus vaccine in 2026?
Hantavirus vaccine in 2026?
6% Chance
$129,605 Vol.
$129,605 Vol.
31. Dez. 2026
6% Chance
$129,605 Vol.
$129,605 Vol.
31. Dez. 2026
This market will resolve to "Yes" if any vaccine intended for humans and inoculating against Hantavirus (including Hantavirus Pulmonary Syndrome (HPS) or Hemorrhagic Fever with Renal Syndrome (HFRS)) receives full approval from the U.S. Food and Drug Administration between market creation and December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.The absence of any licensed hantavirus vaccine, combined with extended clinical development timelines, underpins the market's strong 94.5% implied probability against availability in 2026. As of mid-2026, candidates remain in preclinical or early-phase testing following advances like structural mapping and mRNA approaches, with no Phase 3 efficacy trials underway to meet regulatory standards for approval. A May 2026 Andes virus outbreak on a cruise ship highlighted the disease's severity and spurred research interest, yet historical patterns show vaccine licensing requires years beyond initial lab progress. Traders' consensus aligns with official surveillance data showing low case volumes and no accelerated emergency pathways sufficient for this calendar year, though unexpected regulatory fast-tracking or breakthrough trial results could still alter trajectories before year-end.
This market will resolve to "Yes" if any vaccine intended for humans and inoculating against Hantavirus (including Hantavirus Pulmonary Syndrome (HPS) or Hemorrhagic Fever with Renal Syndrome (HFRS)) receives full approval from the U.S. Food and Drug Administration between market creation and December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.
Markt eröffnet: May 4, 2026, 10:39 AM ET
Volumen
$129,605Enddatum
31. Dez. 2026Markt eröffnet
May 4, 2026, 10:39 AM ETResolver
0x65070BE91...This market will resolve to "Yes" if any vaccine intended for humans and inoculating against Hantavirus (including Hantavirus Pulmonary Syndrome (HPS) or Hemorrhagic Fever with Renal Syndrome (HFRS)) receives full approval from the U.S. Food and Drug Administration between market creation and December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.The absence of any licensed hantavirus vaccine, combined with extended clinical development timelines, underpins the market's strong 94.5% implied probability against availability in 2026. As of mid-2026, candidates remain in preclinical or early-phase testing following advances like structural mapping and mRNA approaches, with no Phase 3 efficacy trials underway to meet regulatory standards for approval. A May 2026 Andes virus outbreak on a cruise ship highlighted the disease's severity and spurred research interest, yet historical patterns show vaccine licensing requires years beyond initial lab progress. Traders' consensus aligns with official surveillance data showing low case volumes and no accelerated emergency pathways sufficient for this calendar year, though unexpected regulatory fast-tracking or breakthrough trial results could still alter trajectories before year-end.
This market will resolve to "Yes" if any vaccine intended for humans and inoculating against Hantavirus (including Hantavirus Pulmonary Syndrome (HPS) or Hemorrhagic Fever with Renal Syndrome (HFRS)) receives full approval from the U.S. Food and Drug Administration between market creation and December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.
Volumen
$129,605Enddatum
31. Dez. 2026Markt eröffnet
May 4, 2026, 10:39 AM ETResolver
0x65070BE91...The absence of any licensed hantavirus vaccine, combined with extended clinical development timelines, underpins the market's strong 94.5% implied probability against availability in 2026. As of mid-2026, candidates remain in preclinical or early-phase testing following advances like structural mapping and mRNA approaches, with no Phase 3 efficacy trials underway to meet regulatory standards for approval. A May 2026 Andes virus outbreak on a cruise ship highlighted the disease's severity and spurred research interest, yet historical patterns show vaccine licensing requires years beyond initial lab progress. Traders' consensus aligns with official surveillance data showing low case volumes and no accelerated emergency pathways sufficient for this calendar year, though unexpected regulatory fast-tracking or breakthrough trial results could still alter trajectories before year-end.
Experimentelle KI-generierte Zusammenfassung mit Polymarket-Daten. Dies ist keine Handelsberatung und spielt keine Rolle bei der Auflösung dieses Marktes. · Aktualisiert
Vorsicht bei externen Links.
Vorsicht bei externen Links.
Häufig gestellte Fragen